GSK reported positive late-stage trial results for multiple cancer therapies throughout July. An experimental drug for small-cell lung cancer showed promising outcomes, while the drug Jemperli met its primary endpoint in a mid-stage trial for rectal cancer. Results demonstrated a clinically significant rate of patients with no detectable signs of cancer for one year or more post-treatment, as confirmed by interim Phase II AZUR-1 data.
GSK reported that its Jemperli therapy met the primary endpoint in the AZUR-1 trial, supporting potential regulatory filings for rectal cancer treatment.
Read the full storyGSK announced that Jemperli met primary goals in a mid-stage trial, with patients showing no detectable signs of cancer for at least one year post-treatment.
GSK's experimental drug for advanced small-cell lung cancer achieved positive results in a late-stage clinical trial.